Low-Dose Hypomethylating Agents in Lower-Risk MDS Yield Promising Outcomes - Medpage Today
8/22/2022 12:00:00 AM2 years 8 months ago
by Mike Bassett
by Mike Bassett
Overall response rates were 67% with decitabine, 48% with azacitidine
Low-dose hypomethylating agents (HMAs) was associated with favorable outcomes in previously untreated lower-risk myelodysplastic syndromes (MDS), according to a long-term analysis of a randomized pha… [+3911 chars]
full article...